Neuren Pharmaceuticals Limited (ASX: NEU)

Neuren Pharmaceuticals Income Statement

Financials in millions AUD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	231.93	14.55	3.2	0.72	0.5
Revenue Growth (YoY)	1493.66%	355.21%	345.89%	44.85%	-96.46%
Cost of Revenue	26.75	0.01	0.01	0.01	0
Gross Profit	205.17	14.54	3.19	0.71	0.49
Selling, General & Admin	5.93	3.43	1.91	1.76	1.71
Research & Development	26.75	12.71	9.52	7.76	9.86
Other Operating Expenses	0.23	1.39	3.6	0.19	0.37
Operating Expenses	32.68	16.14	11.42	9.52	11.57
Operating Income	199.23	-1.6	-11.43	-9.53	-11.57
Interest Income	5.69	0.39	0.04	0.15	0.39
Other Expense / Income	-0.21	-0.53	-0.4	0.53	0.13
Pretax Income	205.12	-0.68	-10.99	-9.91	-11.31
Income Tax	48.04	-0.86	-3.2	-0.72	-0.5
Net Income	157.08	0.18	-7.79	-9.19	-10.82
Net Income Growth	85270.11%	-	-	-	-
Shares Outstanding (Basic)	127	126	118	107	100
Shares Outstanding (Diluted)	131	129	118	107	100
Shares Change	1.44%	9.46%	10.01%	6.88%	0.42%
EPS (Basic)	1.24	0.00	-0.07	-0.09	-0.11
EPS (Diluted)	1.20	0.00	-0.07	-0.09	-0.11
EPS Growth	85614.29%	-	-	-	-
Free Cash Flow	184.89	3.58	-9.98	-8.08	-11.73
Free Cash Flow Per Share	1.41	0.03	-0.08	-0.08	-0.12
Gross Margin	88.47%	99.93%	99.75%	99.16%	99.19%
Operating Margin	85.90%	-10.97%	-357.52%	-1328.59%	-2337.58%
Profit Margin	67.73%	1.26%	-243.79%	-1282.15%	-2185.05%
Free Cash Flow Margin	79.72%	24.60%	-312.17%	-1127.48%	-2369.90%
Effective Tax Rate	23.42%	-	-	-	-
EBITDA	199.25	-1.59	-11.42	-9.52	-11.57
EBITDA Margin	85.91%	-10.90%	-357.27%	-1327.75%	-2336.77%
Depreciation & Amortization	0.02	0.01	0.01	0.01	0
EBIT	199.23	-1.6	-11.43	-9.53	-11.57
EBIT Margin	85.90%	-10.97%	-357.52%	-1328.59%	-2337.58%

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.